The research is the first to study an association between caffeinated coffee and risk of colon cancer recurrence, researchers said.
The patients, all of them treated with surgery and chemotherapy for stage III colon cancer, had the greatest benefit from consuming four or more cups of coffee a day (about 460 milligrammes of caffeine).
These patients were 42 per cent less likely to have their cancer return than non-coffee drinkers, and were 33 per cent less likely to die from cancer or any other cause.
The study included nearly 1,000 patients who filled out dietary pattern questionnaires early in the study, during chemotherapy and again about a year later.
More From This Section
"We found that coffee drinkers had a lower risk of the cancer coming back and a significantly greater survival and chance of a cure," said Charles Fuchs, director of the Gastrointestinal Cancer Centre at Dana-Farber Cancer Institute in Boston.
Most recurrences happen within five years of treatment and are uncommon after that, he noted.
However, Fuchs is hesitant to make recommendations to patients until the results are confirmed in other studies.
A number of recent studies suggested that coffee may have protective effects against the development of several kinds of cancer, including reduced risks of postmenopausal breast cancer, melanoma, liver cancer, advanced prostate cancer.
Fuchs said the research focused on coffee and other dietary factors because coffee drinking - in addition to possibly being protective against some cancers - had been shown to reduce the risk of type 2 diabetes.
He said it's not clear why caffeine has this effect and the question needs further study.
One hypothesis is that caffeine consumption increases the body's sensitivity to insulin so less of it is needed, which in turn may help reduce inflammation - a risk factor for diabetes and cancer, Fuchs said.
The study was published in the Journal of Clinical Oncology.